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Results: The pharmacovigilance program involved 1 general hos-
pital (Ass.2 ‘Isontina’, Gorizia-Italy), 12 pharmacies, and 24 GPs. 
From March 2012 to March 2013, Medigenia enrolled 2074 patients 
(52.4% women; mean age, 69 [8]).The system totally administered 
62,499 drugs (68.2% prescriptions, 28.4% OTC, and 3.4% herbs), 
and 3028 were the DDIs identified among them. GPs received 2738 
alerts for ADR risk (48% moderate risk, 23.2% high risk): treat-
ment was changed 871 times (31.8%).The most frequent alert among 
high risk connected with hemorrhage (87.6%), involving primarily 
acetyl-salicylic acid and warfarin. Moderate risk concerned mainly 
neurologic sequels (38.2%) and involved in particular antineoplastic 
agents and phenytoin.
Conclusion: People taking drugs are not always aware of the health 
risk they are going toward after a multidrug therapy or simply tak-
ing a medicine without asking GP, a trend that is increasing in the 
last years. Medigenia prevents ADR and their health sequels using a 
cloud-based approach for pharmacovigilance.
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Introduction: Drug-induced liver injury (DILI) is the most fre-
quent reason for withdrawal of approved drugs from the market 
and accounts for 7% to 15% of the cases of acute liver failure in 
Europe and the United States. The risk of developing hepatotoxic-
ity involves a complex interplay between the chemical properties of 
the drug, environment factors, age, sex, underlying diseases, and 
genetic factors.
Patients (or Materials) and Methods: OBJECTIVES: To determinate 
the incidence of DILI detected through a pharmacovigilance program 
from laboratory signals in hospitalized patients in La Paz University 
Hospital from July 2007 to December 2010. Secondary objectives: 
(1) characterize patients with DILI; (2) determinate suspected drugs 
of DILI according to therapeutic group; and (3) classification of cases 
according to type of lesion.
Methods: All serum alanine transaminase (ALT) and aspartate 
transaminase (AST) > 3 upper limit normality (ULN) or > 2 ULN 
of gamma glutamil transpeptidasa (GGT) or bilirubin, detected at 
admission to the hospital, including those patients who died in the 
emergency ward or during hospitalization, were monitored prospec-
tively from July 2007 through December 2010. We evaluated each 
patient to assess alternative causes or confirm DILI. The incidence 
was calculated by dividing the number of cases by the number of 
hospitalizations in that period.
Results: We detected 2490 cases of liver enzyme disorders in the 
study period, with an incidence of 146 cases per 10,000 inpatients 
(Poisson 95% CI, 123.3–171.1). Of these, 198 cases (7.95%) were 
secondary to drugs, reporting an incidence of 11.6 cases of DILI 
per 10,000 inpatients (Poisson 95% CI, 6.2–19.7). The median of 
age was 47.6 (24.4) years, and 49.6% were female. Most of the 
DILI (64.6%) occurred during hospitalization and the rest were out-
patients. The hospitalization wards with more cases of DILI were 
Hematology and Internal Medicine (15.7% each one). The main ther-
apeutic groups of suspected drugs of DILI in our study according to 
the ATC classification system were: J. Antiinfectives for systemic use 
(34.1%), L. Antineoplastic and immunomodulating agents (20.1%) 
and N. Nervous system (18.6%). The classification according to the 
type of lesion: 52.5% was cholestatic, 32.3% had hepatocellular 
injury, and 15.2% had mix pattern. The median (range) of ALT level 
was 656.4 (31–14,397 UI/L); AST, 619.8 (12–17,671 UI/L); GGT, 
420.6 (14–5708 UI/L); and BT, 2.11 (0.1–38.2 mg/dL).
Conclusion: (1) One case of 11 inpatients with liver enzyme disor-
ders is drug-induced. (2) Most of DILI occur during hospitalization. 
(3) The main drugs associated with DILI are antibiotics included in 
group J of the ATC classification system.
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Introduction: The assessment of the adverse drug reactions risk is 
an important factor in drug safety monitoring system. The aim of 
our study was to assess knowledge and attitudes of pharmacologi-
cally educated and pharmacologically noneducated students from the 
University of Montenegro regarding drug safety risk.
Patients (or Materials) and Methods: In this cross-sectional study, a 
self-completion questionnaire was delivered to 63 pharmacologically 
educated students (medical students who attended Pharmacology 
course and passed exams within it), 50 pharmacologically nonedu-
cated students (medical students who attended Pharmacology course 
but did not pass exams within it), and 50 students from other non-
medical faculties at the University of Montenegro.
Results: As expected, pharmacologically educated students are 
considered to be better informed about ADRs than other partici-
pants (P < 0.01). Prescription drugs were ranked as less dangerous 
than self-medication by all participants. Anticoagulants were con-
sidered the most dangerous drugs by pharmacologically educated 
students (median, 7.5; scale, 1–10; interquartile range, 3.75–8), 
and antidepressants, anxiolytics, and hypnotics by pharmacologi-
cally noneducated students (median, 8, all). Information about drug 
safety significantly influenced the choice of therapy by both groups 
of students questioned (median, 8–10, all).
Conclusion: On the basis of the aforementioned results, it can be 
concluded that when risk of adverse drug reactions is in question, 
pharmacologically educated students are much better informed than 
pharmacologically noneducated medical students and students from 
nonmedical faculties. Additional educational efforts are necessary to 
build awareness among general population of adverse drug reactions.
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Introduction: The knowledge of frequency, character, severity, and 
other peculiarities of adverse reactions (ADR) as well as of dynamic 
